

200 Park Avenue, 17th Floor, New York, NY 10166
sirillp.com | P: (212) 532-1091 | F: (646) 417-5967

July 18, 2022

VIA EMAIL AND FED EX

Kizzmekia Corbett, MD
Harvard T.H. Chan
School of Public Health
677 Huntington Avenue
Boston, MA 02115
kizzmekia_corbett@hsph.harvard.edu

Re: *Selection of Spike Protein for Moderna/NIH mRNA COVID-19 Vaccine*

Dear Dr. Corbett:

On behalf of Informed Consent Action Network (“ICAN”), we write to inquire as to your selection of the spike protein in SARS-CoV-2 as the basis for the Moderna/NIH mRNA COVID-19 vaccine that you were integral in developing and inventing.

Selection of the spike protein for the vaccine appears to have been inappropriate and unscientific. The following statements have been publicly made by a former Vice President and Senior Chief Scientific Officer of Allergy and Respiratory Research at Pfizer:¹

1. To create a vaccine with ongoing efficacy, one should pick the part of the virus that is most genetically stable so that it is least likely to mutate away from induced immunity. This suggests one would never pick the spike protein.
2. One would also pick the part of the virus that is most different from humans. This is a key to side effect mitigation; if you train immune response to something that looks like parts of the human body, you will get an auto-immune response. Your body will attack itself. Adhering to this principle would also lead to not picking spike protein, which has some similarity to many parts of humans.
3. In vaccine design, one selects for things that are not toxic in their own right. This, again, points away from using spike protein.

These are at least three principles that “teach away” from selecting spike protein as the target for vaccine design. ICAN respectfully requests an explanation as to why, despite the

¹ See <https://odysee.com/@MaajidNawaz:d/EP8-Radical:9>.

foregoing, the spike protein was selected when you developed Moderna's Covid-19 vaccine. ICAN looks forward to your prompt response.

Very truly yours,

A handwritten signature in blue ink, appearing to be 'AS', written in a cursive style.

Aaron Siri, Esq.

Elizabeth A. Brehm, Esq.